Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

As of April 30, 2025, there are 82 publicly listed companies in China engaged in the in vitro diagnostics (IVD) industry. Among them, 61 companies focus primarily on IVD, while 21 have IVD as part of their broader business portfolios.

Wuhan Thalys Biotechnology Co.,Ltd. ("Thalys") announced that it has signed a contract with Norwegian high-tech molecular diagnostic company Genetic Analysis ("GA") for the laboratory self-built project testing (LDT) for the Chinese market.

Specific nuclear proteins act as a glue to pack genetic material in an absurdly small space in the human body. Proteins “gluing” DNA are called linker histones, and hold their secret in their electric charge. They are strongly positively charged, fusing to the strongly negatively charged DNA.

Expects Q4 2021 revenue of $29-31 million; Full year 2021 revenue of $109-111 million

ISB-led study shows unvaccinated pregnant people with COVID-19 are more likely to have poor birth outcomes even if they did not experience severe respiratory problems during infection.

According to public statistics, the transaction value of the global TOP10 healthcare M&A deals in 2021 will all be more than $3 billion, of which Thermo Fisher’s acquisition of PPD for $17.4 billion ranks first

Illumina announced a bevy of new business partnerships, products, and technology advances Monday at the 2022 JP Morgan Healthcare Conference, held virtually this week.

SQI Diagnostics said on Monday that it has signed a definitive agreement to acquire Precision Biomonitoring's SARS-CoV-2 testing business and related molecular diagnostic technology for $6.825 million in cash and stock.

A variety of diagnostic companies, including Danaher, PerkinElmer, Cue Health, T2 Biosystems, SomaLogic, and Fluidigm, announced preliminary earnings results for the fourth quarter and full year 2021 on Tuesday.

Due to the substantial increase in overseas sales of the COVID-19 Test kit launched in 2021, many listed IVD companies estimate that their profits will surge in 2021.

Scientists have just slotted into place a big piece of the puzzle that explains how our blood cells mount their first line of defence against viruses. They hope this discovery will help them one day better control the response to either boost it or calm it down as appropriate.